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Lyophilized unilamellar liposomes (ULV), the dosage form of choice for shelf-life, revert upon reconstitution to the larger multilamellar
liposomes (MLV), which is detrimental to the many carrier-mediated therapies that require small particles. High doses of sugars such as
trehalose, sucrose and others, included in the original formulations for cryoprotection, were shown to prevent the conversion to MLV. In this
study we set out to test whether hyaluronan (HA), the surface-bound ligand in our previously developed targeted bioadhesive liposomes
(BAL), can also act as a cryoprotectant. The studies included structural and physicochemical characterization of original and reconstituted
hyaluronan-ULV (HA-ULV). For each HA-ULV, similar regular ULV (RL-ULV) served as controls. Four properties were tested: particle size,
zeta potential, encapsulation efficiency and half-life of drug release (s1/2), for three drugs—chloramphenicol (CAM), vinblastine (VIN) and
mitomycin C (MMC). Encapsulation efficiencies of the original systems were quite alike for similar RL-ULV and HA-ULV ranging from
25% to 70%. All systems acted as sustained-release drug depots, s1/2 ranging from 1.3 to 5.3 days. Drug species and lipid composition were
the major determinants of encapsulation and release magnitudes. By all tests, as anticipated, lyophilization generated significant changes in
the reconstituted RL-ULV: 17-fold increase in diameter; tripling of zeta potential; 25–60% drop in encapsulation efficiencies; 25–30%
decrease in s1/2. In contrast, the reconstituted HA-ULV retained the same dimensions, zeta potentials, encapsulation efficiencies and s1/2 of
the original systems. These data clearly show HA to be a cryoprotectant, adding another clinically relevant advantage to HA-BAL. We
propose that, like the sugars, HA cryoprotects by providing substitute structure-stabilizing H-bonds.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Unilamellar liposome; Hyaluronan; Bioadhesive; Lyophilization; Cryoprotection1. Introduction
Lyophilization (freeze-drying) is the method of choice
for long-term storage of biological materials, including free
and drug-encapsulating liposomes [1–3]. In the process,
most of the water molecules are excluded from the specimen
and the aqueous suspension becomes a powder (lyophili-
zate) that can be stored at selected, even ambient, temper-
atures. Prior to use, reconstitution of the particulate system
is achieved by rehydration of the dry powder [4]. Lyophi-0005-2736/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0005-2736(03)00106-8
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carbodiimide; HA, hyaluronan, hyaluronic acid; MLV, multilamellar
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glycol; RL, regular liposomes; ULV, unilamellar vesicles; VIN, vinblastine
* Corresponding author. Tel.: +972-3-6409822; fax: +972-3-6406834.
E-mail address: rimona@post.tau.ac.il (R. Margalit).lization of multilamellar liposomes (MLV) and subsequent
recovery of the very same liposome type—MLV—is simple
and straight forward [2,3]. With unilamellar liposomes
(ULV) the situation is more complex. Unless specific
precautions are taken, the small original ULV revert, upon
lyophilization and reconstitution, to the much larger MLV
[2,5,6].
It is well recognized that small particle size (on the
nanoscale) is critical for carrier-mediated treatment of path-
ologies that require systemic administration and long-term
circulation [7–12]. Relapse of the small-sized ULV into the
much larger MLV is obviously detrimental to such treat-
ments. A solution to the problem that allows recovery of
ULV from lyophilized ULV powders was found to be the
inclusion of relatively high concentrations (f 30%) of
cryoprotectants, such as trehalose, sucrose, mannose or
glucose, in the original ULV preparation [5,6,13]. The role
attributed to these cryoprotectants is replacement of struc-
ture-stabilizing water-based hydrogen bonds at the liposo-ed.
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The downside of this approach is that these sugars are also
present in the formulation administered to the patient.
In this report, we offer another approach to cryoprotec-
tion, which fits bioadhesive liposomes (BAL) and does not
require the inclusion of additives, such as the sugars listed
above, in the formulation.
BAL are regular liposomes (RL), modified by the cova-
lent anchoring of ligands such as collagen, gelatin, EGF or
hyaluronan (HA) to their surface [14–23]. We have devel-
oped and investigated these liposomes originally for topical
and regional, and lately also for systemic, applications [14–
21]. We have found that the surface-bound HA provides
liposomes with the advantages of long circulation and of
high affinity to recognition sites that are overexpressed in
tumors [22,23]. Focusing here on HA-BAL, the abundance
of hydroxyl residues on the liposomal surface has lead us to
hypothesize that this HA coat may also act as a cryopro-
tectant for lyophilized ULV. This would eliminate the need
to include sugar residues in the formulation and be espe-
cially beneficial to some patients for which the sugar
residues (particularly at the doses used) may trigger unac-
ceptable adverse effects.
To pursue this hypothesis, we prepared several systems
of RL and of HA bioadhesive ULV in which we
encapsulated vinblastine (VIN), mitomycin C (MMC) or
chloramphenicol (CAM). Each original preparation, regu-
lar and bioadhesive, was characterized by structural and
by physicochemical properties, focusing on EM, particle
size, zeta potential, efficiency of drug encapsulation and
kinetics of drug efflux. The systems were then lyophi-
lized, reconstituted by rehydration, and the structural and
physicochemical properties determined anew. We also
tested the influence of two liposome parameters on the
lyophilization/reconstitution properties: lipid composition,
tested for both the regular and the bioadhesive systems,
and (for the BAL) the density of the HA coat at the
liposomal surface.
As will be shown, the results confirmed the working
hypothesis. The present results reveal another advantage for
the HA-BAL—the ability to act as a cryoprotectant for
unilamellar liposomes.2. Materials and methods
2.1. Materials
High-purity (Phospholipon 100) soybean phosphatidyl-
choline (PC) was a kind gift from Nattermann phospholi-
pid GMBH (Germany). All other high-purity lipids, ethyl-
dimethyl-aminopropyl-carbodiimide (EDC) and CAM were
purchased from Sigma Chemical Company, St. Louis, MO.
[3H]Vinblastine (VIN) and [3H]cholesterol were purchased
from Amersham (Buckinghamshire, England) and found to
be stable. MMC was a kind gift from Dexon Ltd., Israel.HA (hyaluronic acid) from bovine trachea was a kind gift
from Hyal Pharmaceutical Corporation, Canada. Dialysis
tubing (molecular weight cutoff of 12000–14000) was
from Spectrum Medical Industries (Los Angeles, CA,
USA). Polycarbonate membranes were from Nucleopore
(Pleasanton, CA, USA). All other reagents were of ana-
lytical grade.
Liposome extrusion was performed with the Lipex
extrusion device (Vancouver, Canada). Centrifugation was
performed using a Beckman Optima TLX, tabletop ultra-
centrifuge. Lyophilization was performed with an Alpha 1-4
freeze drier (CHRIST, Germany). Absorbance spectra were
measured using a Cary UV–Visible spectrophotometer and
a Thermomax microplate reader. Liquid scintillation count-
ing was performed with a Kontron Analytical Betamatic.
ALV-NIBS (Berlin, Germany) was used for particle sizing
and the Malvern Zetasizer IV (MA, USA) was used to
determine the zeta potential. Scanning electron microscopy
(SEM) was done with a JSM-840A, Joel Microscopy
(Japan) after coating the lyophilized powder with gold using
the SEM coating unit E5100 (England).3. Methods
3.1. Liposome preparation and drug encapsulation
Regular MLV, the ‘‘raw material’’ for RL-ULV, were
prepared essentially as previously described [14,18,20].
Four liposome formulations, differing in their lipid compo-
sition, were prepared for each encapsulated drug as follows:
Formulation A—phosphatidyl ethanolamine (PE)/phospha-
tidyl choline (PC) (5:95), Formulation B—PE/PC (10:90),
formulation C—PE/PC (20:80) and formulation D PE/CH/
PC (20:20:60). The numbers in parenthesis are the mole
ratios. All formulations were prepared at the same liposome
concentration of 50 mg lipid/ml. For drug-free liposomes
the swelling solution was phosphate-buffered saline (PBS)
at a pH of 7.2. The same buffer was used for the drug-
encapsulating liposomes and the drugs were introduced
through the swelling solution.
ULV were obtained by extrusion of the MLV through the
Lipex device, operating the extrusion device at room tem-
perature and under nitrogen pressures of 200 to 500 psi. The
extrusion was carried out in stages using progressively
smaller pore-size membranes, with several cycles per
pore-size [21].
3.2. Liposome modification
The modification was performed on the ULV, according
to our previously reported process [14,15,20]. Briefly, HA
was dissolved in water and pre-activated by incubation with
EDC, at pH 4 (controlled by titration with HCl) for 2 h at 37
jC. At the end of this step, the activated HAwas added to a
suspension of PE-containing liposomes in 0.1 M borate
Table 1
The effects of lyophilization on particle size of RL and HA-BAL
Liposome Liposome diameter (nm)
specification
Pre-lyophilization Post-lyophilization
RLa 138F 43b 2330F 735
BAL0.5 150F 40 224F 100
BAL2.0 172F 90 240F 150
BAL5.0 195F 65 300F 180
a RL denotes regular liposomes; BAL0.5, BAL2.0 and BAL5.0 denote the
hyaluronan bioadhesive liposomes, prepared at different hyaluronan coating
densities (see Section 2 for details).
b Each value is an average of seven determinations.
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incubated for 24 h at 37 jC. At the end of incubation, the
liposomes were separated from excess reagents and by-
products by centrifugation (1.3 105g, 4jC and 40 min)
and repeated washings. When modifying drug-encapsulat-
ing liposomes, all steps were carried out in the presence of
drug in the external medium, in order to minimize drug loss
during the process. HA concentrations in the reaction
mixture were 0.5, 2.0 or 5.0 mg/ml, and the resultant HA-
BAL were denoted BAL0.5, BAL2.0 andBAL5.0.
3.3. Drug diffusion
The kinetics of drug diffusion was studied as previously
described [18,20,21]. Briefly, a suspension of liposomes
(0.5–1.0 ml) was placed in a dialysis sac and the sac was
immersed in a continuously stirred receiver vessel, con-
taining drug-free buffer (PBS at pH 7.2). The buffer
volume in the receiver vessel was 10- to 16-fold higher
than that of the liposome sample in the dialysis sac. At
designated periods, the dialysis sac was transferred from
one receiver vessel to another, containing fresh (i.e., drug-
free) buffer. Drug concentration was assayed in each
dialysate and in the sac (at the beginning and end of each
experiment).
In order to obtain a quantitative evaluation of drug
release, experimental data were analyzed according to a
previously derived multi-pool kinetic model [18,21]. Eq. (1)
expresses the relationship between free and dependent
variables for this model.
f ðtÞ ¼
Xn
j¼1
fjð1 expkjtÞ ð1Þ
Where t denotes time, f(t) is the cumulative drug released
into the dialysate at time t, normalized to the total drug in
the system at time = 0, fj is the fraction of the total drug in
the system occupying the jth pool at time = 0, and kj is the
rate constant for drug diffusion from the jth pool.
3.4. Encapsulation efficiency
Defined as the ratio of entrapped drug to the total drug in
the system, encapsulation efficiency was determined by two
independent methods: (1) Centrifugation. Samples of com-
plete liposome preparation (i.e., containing both encapsu-
lated and unencapsulated drug) were centrifuged as
described above. The supernatant, containing the unencap-
sulated drug, was removed and the pellet, containing the
liposomes with encapsulated drug, was resuspended in
drug-free buffer. Drug was assayed in the supernatant and
in the pellet, as well as in the complete preparation, from
which the encapsulation efficiency was calculated, and
conservation of matter was verified. (2) Efflux kinetics.
As discussed above, data analysis yields the parameter fj.
When the efflux experiment was performed on samples
from the complete liposome preparation, the magnitude offj for the pool of encapsulated drug was also the efficiency
of encapsulation.
3.5. Lyophilization and reconstitution
Lyophilization of liposome suspensions was performed
on 1.0-ml aliquots. Samples were frozen for 2–4 h at  80
jC and lyophilized for 48 h. Reconstitution was to original
volume using distilled water.
3.6. Quantitative determinations
Cholesterol (CH) and vinblastine were assayed using
traces of [3H]cholesterol and [3H]vinblastine, respectively.
MMC was assayed by its absorbency at 365 nm, which was
linear in the range of 0–100 Ag/ml, with extinction coef-
ficients of 0.0127 and 0.0153 ml/Ag cm in buffer and in 5%
deoxycholate (DOC), respectively. CAM was assayed by its
absorbency at 280 nm, found to be linear in the concen-
tration range of 0–100 Ag/ml, with extinction coefficients of
0.0315 and 0.0354 ml/Ag cm in buffer and in 5% DOC,
respectively.
Statistics was done using Student’s t test.4. Results
4.1. Structural properties
4.1.1. Particle size
Particle sizing, pre- and post-lyophilization, was per-
formed using the ALV-NIBS device as detailed under Section
2. Typical results, presented in Table 1, demonstrate the
effects of the HA coat on retention of liposome size. The
original liposomes, irrespective of whether they are regular or
bioadhesive, were unilamellar (as expected) with diameters in
the range of 100 nm. Upon lyophilization and reconstitution,
the RL were found to undergo a substantial increase in
diameter size—17-fold higher than the original particles.
This high level of increase, yielding liposomes with an
average diameter of 2400 nm, is indicative of the expected
relapse of ULV to MLV, in the absence of cryoprotectants. In
contrast, the three formulations of bioadhesive ULV that were
Fig. 1. SEM of lyophilized unilamellar liposomes. (A) RL. (B) HA-BAL.
Both micrographs were taken under the same magnification as indicated in
the figure.
D. Peer et al. / Biochimica et Biophysica Acta 1612 (2003) 76–82 79surface-coated with HA showed good retention of the ULV
size range, post-lyophilization and reconstitution.
4.1.2. Zeta potentials
The zeta potentials measured pre- and post-lyophiliza-
tion are listed in Table 2. The zeta potentials of the RL-
ULV, pre- and post-lyophilization, are close to zero, but
were tripled post-lyophilization and reconstitution. The
zeta potentials of the original (i.e., pre-lyophilization)
bioadhesive ULV are negative, increasing in magnitude
with the increase in the density of the HA coat. Lyophi-
lization and reconstitution generated small differences in
the respective potentials. The surface modification is done
on pre-formed liposomes (see methods), hence all of the
HA anchored covalently to the lipid are originally on the
outermost leaflet of the lipid bilayer membrane. Were the
lyophilized powders composed of individual lipid mole-
cules and lipid–HA conjugates, it is conceivable that in
the course of reconstitution by rehydration, some of the
lipid-attached HA would reside in the interior of the
liposomes. This, in turn, would make the zeta potential
of a reconstituted liposome less negative than the respec-
tive original system. The observation that this did not
occur is taken as an indication that structural liposomal
elements were preserved in the lyophilized BAL. It also
implies that the HA remained at the surface, in a position
to replace the lost water-originating hydrogen bonds.
4.2. SEM
The results obtained from SEM of the lyophilized lip-
osome powders are illustrated in Fig. 1A for RL-ULVand in
Fig. 1B for the bioadhesive ULV. The lyophilizate of the
RL-ULV (1A) is seen to be composed of large particles,
ranging from 1000 to 4000 nm. In contrast, the dominant
particles in the lyophilizate of the bioadhesive ULV (1B) are
much smaller, at the edge of detection under the magnifi-
cation used. These findings fit well with the above presented
results of liposome dimensions (Table 1) and zeta potentials
(Table 2).
4.3. Efficiency of encapsulation
Typical magnitudes obtained for the efficiency of encap-
sulation for each of the tested drugs in all four liposome
formulations (see methods for details), in both regular andTable 2
f potential of HA-coated liposomes pre- and post-lyophilization
Liposome f potential (mV)
specification
Pre-lyophilization Post-lyophilization
RL 0.012F 0.003a 0.031F 0.002
BAL0.5  6.21F 0.45  8.4F 1.9
BAL2.0  13.0F 0.90  15.4F 4.5
BAL5.0  15.4F 1.10  18.6F 3.7
a Each values is an average of seven determinations.coated vesicles, pre- and post-lyophilization, are shown in
the three parts of Fig. 2.
Starting with the data for CAM, shown in the top part of
Fig. 2, several findings stand out: increasing the PE concen-
tration in the liposome formulation, from 5 to 10 to 20 mol%
(formulations A, B and C) resulted in a substantial increase in
the efficiency of encapsulation for both regular and coated
ULV. For both types of liposomes, replacing 20 mol% of the
PC by CH (formulation D) resulted in a further increase of
encapsulation efficiency. For the coated liposomes in all
tested formulations, the lyophilization and reconstitution
did not generate any change in the encapsulation efficiency.
In contrast, in all RL formulations lyophilization and recon-
stitution resulted in decreased encapsulation efficiencies.
Similar trends were found for the MMC and for the VIN
systems (shown in the middle and bottom parts of Fig. 2,
respectively). For the latter, encapsulation efficiencies of the
Table 3
Efflux of encapsulated drugs from RL and from BAL, pre- and post-
lyophilization
Drug Efflux half-life (days)
RL BAL
Pre Post Pre Post
Chloramphenicol 5.26F 0.53 3.61F 0.05 4.00F 0.54 4.33F 0.45
Mitomycin C 1.73F 0.27 1.28F 0.10 1.99F 0.23 2.35F 0.47
Vinblastine 1.68F 0.22 1.32F 0.24 3.20F 0.27 4.72F 0.53
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4.4. Kinetics of drug efflux
For all systems studied, we found the data to fit a two-
term kinetic equation (see Eq. (1)), corresponding to:
f ðtÞ ¼ f1ð1 expk1tÞ þ f2ð1 expk2tÞ
where indices 1 and 2 are for the unencapsulated and
encapsulated drugs, respectively.
Intrinsic drug properties were found, as expected, to be
the dominant factor dictating the efflux rate constant of the
encapsulated matter, and its sensitivity to the different
liposomal systems (RL and BAL, each type pre- and post-
lyophilization). Unlike the case of encapsulation efficiency,
sensitivity to lipid composition—for each drug within a
given liposomal system—was quite low. Increase in mol%
PE either made no change or slightly increased the efflux,
the addition of CH (for the same % mole PE) induced a
slight decrease in the efflux, but none of these differencesFig. 2. The effects of lyophilization and reconstitution of regular and of
hyaluronan bioadhesive unilamellar liposomes on the efficiency of drug
encapsulation. Top part is the chloramphenicol (CAM) data, middle part is
the mitomycin C (MMC) data and bottom part is the vinblastine (VIN) data.
Encapsulation of each drug, pre- and post-lyophilization, is reported for
four liposome formulations: (A) PE/PC (5:95), (B) PE/PC (10:90), (C) PE/
PC (20:80) and (D) PE/CH/PC (20:20:60). Light-shaded and dark-shaded
bars are for pre- and post-lyophilization, respectively. Each bar is an
average of three determinations and the error bars represent the standard
deviations. *, ** and *** indicate P< 0.05, P < 0.01 and P < 0.001,
respectively.were statistically significant (data not shown). Therefore, for
each drug in a given liposomal system, the rate constants for
the efflux of the encapsulated drug (i.e., k2) were trans-
formed into the corresponding half-life values, averaged
over all lipid compositions tested, and listed in Table 3.
All systems performed as sustained-release drug depots,
half-lives ranging from 1.3 to 5.3 days. Among the three
drugs tested, CAM had the slowest diffusion. The data
(Table 3, first row) show that in the pre-lyophilized state,
CAM diffusion was slower from the regular than from the
BAL. Lyophilization, however, did not change the efflux
from the BAL, while it made a significant change—increas-
ing the efflux—for the regular ones. These data fit with the
findings reported in previous sections of this communica-
tion that the lyophilized and reconstituted unilamellar BAL
remain quite similar to the original ones, whereas the RL
undergo drastic changes. For MMC (Table 3, second row)
the efflux from RL and BAL is quite similar in the original
state. Lyophilization and reconstitution generated slight and
opposite changes in MMC efflux from the two types of
liposomes—increase in the case of the regular and decrease
in the case of the bioadhesive, systems. Similar trends, with
the obvious drug-specific quantitative differences, are seen
for the efflux of VIN (Table 3, third row).5. Discussion
Lyophilization and reconstitution of a pharmaceutical
product are usually viewed as technical procedures per se
that do not change the nature of the original product and
therefore do not require molecular investigative efforts [1].
This situation is changed when it comes to unilamellar
liposomes [2,5,6,13], where pursuit of the effects of lyophi-
lization becomes a necessity, in particular for therapies in
which a small particle size is critical [7–12].
The well-recognized phenomena discussed in the intro-
duction of this report, that lyophilized small (unilamellar)
liposomes revert to the much larger MLV [2,5,6,13], was
reaffirmed by findings of this study. In the absence of any
cryoprotectant in the system, lyophilization and reconstitu-
tion had a substantial effect on the size of regular unila-
mellar liposomes. The quantitative evidence provided
through particle size analysis shows a 17-fold increase in
diameter size, from the original diameter range of 140 nm,
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The EM results (Fig. 1A) add qualitative support to this
radical increase in size.
The findings of this study clearly validate the working
hypothesis—that HA, anchored to the surface of BAL, acts
as a cryoprotectant of lyophilized ULV. Unlike the RL-
ULV (discussed above), lyophilization and reconstitution
generated a relatively small increase ( < 1-fold) in the
original size of HA-ULV. This is seen (Table 1) for three
different HA-ULV formulations, which vary in their bio-
adhesive coat. The original diameters, in the range of 150,
170 and 200 nm for the three formulations, increased to
respective diameters in the range of 220, 240 and 300 nm.
Furthermore, as clearly seen from the standard deviation in
Table 1, the size distribution broadened from the original
to the reconstituted systems. The original bioadhesive
systems (as any preparation in which ligands are attached
to the liposomal surface) probably contain some regular (or
poorly bioadhesive) liposomes. These, upon lyophilization
and reconstitution, would obviously revert to the larger
MLV. If the share of the RL, within the bioadhesive
preparation, is not enough for resolution into two distinct
populations, their conversion to larger particles could
account for the slight increase seen (for the whole system)
in diameter size and for the broader distribution. Conse-
quently, it might be that in terms of particle size, the
protection offered by the HA coat is even better than what
the data show. As in the case of the RL, the EM data
concur with the quantitative particle size analysis: the HA-
coated liposomes remained small (Fig. 1B), where the RL
increased in size (Fig. 1A).
Another demonstration that the BAL retained their struc-
tural features throughout the drying and the reconstitution
comes from the zeta potentials (Table 2). For each bioadhe-
sive liposome formulation, the zeta potential remains quite
the same for the original and for the lyophilized and
reconstituted systems. Were the dry state an amorphous
powder of lipid molecules, some of the HA originally
localized at the liposomal surface should have ended inside
the liposome. Were this to happen, the reconstituted lip-
osomes would have had less negative zeta potentials. The
data suggest that this did not happen, indicating structural
elements were conserved in the dry state, the HA remaining
through the drying and rehydration at the surface of the
liposome.
Encapsulation efficiency and efflux kinetics are two key
physicochemical parameters that influence drug delivery
performance of particulate carriers. Both parameters were
tested for three different drugs to evaluate how lyophiliza-
tion and reconstitution affect them. Three distinct features of
this probing, shown in Fig. 2, clearly stand out: In all cases,
replacing PC by increasing levels of PE, from 5 to 20 mol%
(systems A to C), and a further replacement of PC by 20
mol% CH (system D), resulted in an increase of encapsu-
lation efficiencies. For a given type of liposome, increase in
liposome concentration and decrease in the standard electro-chemical potential of the drug in the liposome [(lD
o )liposome]
were identified long ago as two independent parameters that
generate increase in encapsulation efficiency [21]. Since the
lipid concentration was held constant in all systems tested,
the increase in encapsulation efficiency (within each lip-
osome type, i.e., ULV or MLV) is attributed to the changes
in lipid composition. The observation that the same trend
was seen for different drugs is further support that this is a
liposome-related phenomena, not restricted to a specific
drug or liposome type.
As also seen in Fig. 2, for each of the drugs in all four
lipid-different formulations, encapsulation efficiencies in the
RL dropped from the original to the reconstituted systems.
This is another indication that the lyophilization and recon-
stitution change regular, unprotected, ULV. This drop is also
consistent with the conversion from ULV to MLV, since for
the same lipid concentration and composition, the liposome
(i.e. particle) concentration decreases from ULV to MLV.
Lowering liposome concentration, as already indicated
above, tends to reduce encapsulation efficiency [21].
For CAM and MMC, encapsulation efficiency in the
BAL remained unchanged from the original to the recon-
stituted systems; another indication that the HA offers
effective cryoprotection. For vinblastine in the BAL, encap-
sulation efficiency is seen to increase from the original to
the reconstituted systems. Taking into account that, unlike
the other two drugs, vinblastine is quite lipophilic, it may be
that in the course of lyophilization and reconstitution,
vinblastine relocalized within the liposome, gaining a state
of lower (lD
o )liposome. We have yet to pursue the molecular
origins of this phenomena, yet regardless of the origins, for
the task of drug delivery it is a change in a positive
direction.
The effects of lyophilization and reconstitution on the
half-life of drug release—a direct measure of carrier per-
formance as a sustained-release drug depot—are listed in
Table 3. Since drug specifications are the major factor
dictating the kinetics, this tends to reduce the impact of
lyophilization and reconstitution. Yet, some common trends
are observed. For all three drugs, efflux from the RL
increased after lyophilization. In contrast, lyophilization
and reconstitution of the BAL either made no change
(CAM) or slowed down the efflux (MMC and VIN). This
indicates that for BAL, the process of lyophilization and
reconstitution either retains or improves the performance as
sustained-release drug depots.
Lyophilization of liposome suspensions obviously
removes water molecules, including those at the surface of
the liposomes that are involved in structure-stabilizing
hydrogen bonding [5,6,13]. It is the loss of these hydrogen
bonds that apparently destabilizes the unilamellar structure
to the point that MLV are recovered upon rehydration of the
dry lipid powder [5,6,13]. The cryoprotection mechanism
attributed to the sugar molecules stems from their ability to
engage in hydrogen bonding that substitutes for those lost
water molecules [5,6,13].
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tion by HA also involves retention of structure-stabilizing
hydrogen bonding at the liposomal surface. HA could
perform this function in several ways: HA is known to
engage extensively in hydrogen bonding—to itself (intra-
and intermolecular) and to other molecules, including
water [24–28]. In addition, HA is known for its extensive
ability to adsorb water molecules, as well as for its
reluctance to relinquish all of them upon drying [28].
On the basis of these properties we offer the following
scenario: The original BAL could already benefit from
structure stabilization that stems from the hydrogen bond-
ing abilities of HA and from its water-holding capacity.
These liposomes may be less vulnerable, from the begin-
ning, to structural destabilization brought upon by
removal of water molecules. As the drying process pro-
gresses, the HA can substitute—just as the sugar residues
do—hydrogen bonding instead of the lost water mole-
cules, further preventing structural destabilization of the
dried systems.
In conclusion, on the basis of the data reported in this
study (coming from several independent lines of inves-
tigation), HA anchored at the surface of unilamellar BAL
clearly acts as a built-in cryoprotectant. This HA ability
is not restricted to a specific drug, specific liposome
formulation or ULV size range—similar cryoprotection
was effective for HA-ULV of 60–70 nm diameter pre-
pared for systemic administration [22,23]. There is an
obvious need for further probes into the mechanism(s)
involved, yet the benefits for drug delivery are already
evident. The dried BAL can be taken ‘‘off the shelf’’,
reconstituted and administered to the patient without the
risks of change in particle size (that would undermine the
therapy) and without the need to include high levels of
foreign matter in the formulation that could cause adverse
effects.Acknowledgements
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